Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 215 participants.

Also called NCT03482180

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 215 participants (enrolled count) (from the registry)
Sponsor
Kuhnil Pharmaceutical Co., Ltd. (from the registry)
Registry
  • NCT NCT03482180
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03482180. Randomized; double masking; primary purpose treatment. Start 2016-05-04 (actual); primary completion 2017-05-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
Condition
Dyslipidemias
Intervention (Drug)
KI1106 4g, QD
Intervention (Drug)
Atorvastatin Calcium 20mg, QD
Lead sponsor
Kuhnil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03482180
Content hash
6be066d3c8bba4d8a1385b54ad09dbd33fba65291dedc61d8b350c0fe8377b4b